Log in

NASDAQ:OPTR - Optimer Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Optimer Pharmaceuticals, Inc (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:OPTR
CUSIP68401H10
Phone+1-201-3338819

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive OPTR News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTR and its competitors with MarketBeat's FREE daily newsletter.


Optimer Pharmaceuticals (NASDAQ:OPTR) Frequently Asked Questions

What is Optimer Pharmaceuticals' stock symbol?

Optimer Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPTR."

Has Optimer Pharmaceuticals been receiving favorable news coverage?

Media stories about OPTR stock have trended negative on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Optimer Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for Optimer Pharmaceuticals.

Who are some of Optimer Pharmaceuticals' key competitors?

What other stocks do shareholders of Optimer Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Optimer Pharmaceuticals investors own include Stewart Enterprises (STEI), Sirius XM (SIRI), ShoreTel (SHOR), PennantPark Investment (PNNT), Hansen Medical (HNSN), Geron (GERN), Glacier Bancorp (GBCI), Polarityte (COOL), Abraxas Petroleum (AXAS) and Ares Capital (ARCC).

What is Optimer Pharmaceuticals' official website?

The official website for Optimer Pharmaceuticals is http://www.optimerpharma.com/.

How can I contact Optimer Pharmaceuticals?

Optimer Pharmaceuticals' mailing address is 101 Hudson St Ste 3501, JERSEY CITY, NJ 07302-3915, United States. The biopharmaceutical company can be reached via phone at +1-201-3338819.


MarketBeat Community Rating for Optimer Pharmaceuticals (NASDAQ OPTR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Optimer Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What is a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel